

### **IMAGE**



# Infographic of primary trabeculectomy for advanced glaucoma study (TAGS)

Clarissa E. H. Fang <sup>1</sup>, Rashmi G. Mathew and Christin Henein <sup>1</sup>

© The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021, Corrected publication 2021

Eye (2022) 36:915; https://doi.org/10.1038/s41433-021-01701-z

Pragmatic multicentre randomised controlled trial showed that primary trabeculectomy had similar quality of life and safety outcomes and achieved a lower intraocular pressure compared with primary medication in newly diagnosed advanced openangle glaucoma.

EQ-5D-5L, EuroQol Group's 5 dimension 5-level health status questionnaire; HUI-3, health utility index mark 3; GUI glaucoma utility index; SITA, Swedish interactive threshold algorithm; QOL, quality of life; IOP, intraocular pressure. Reference to original article: King AJ, Hudson J, Fernie G, Kernohan

MMC, Mitomycin C; VFQ-25, visual function questionnaire-25;

A, Azuara-Blanco A, Burr J, et al. Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS). BMJ. 2021; 373:n1014. https://doi.org/10.1136/bmj. n1014.

# PRIMARY TRABECULECTOMY FOR ADVANCED **GLAUCOMA: PRAGMATIC MULTICENTRE RANDOMISED CONTROLLED TRIAL (TAGS)**

King A.J, Hudson J, Fernie G, Kernohan A, Azuara-Blanco A, Burr J et al. Primary trabeculectomy for advanced glaucomo pragmatic multicentre randomised controlled trial (TAGS) BMJ 2021; 373 :n1014 doi:10.1136/bmj.n1014

Advanced glaucoma at presentation is the biggest risk factor for lifetime blindness



27 secondary care glaucoma departments in UK



453 adults presenting with newly diagnosed advanced open angle glaucoma

High-risk of trabeculectomy failure e.g. previous conjunctival surgery, complicated cataract surgery

PRIMARY TRABECULECTOMY vs PRIMARY MEDICAL TREATMENT

Secondary glaucoma and primary angle-closure glaucoma

**AUTHOR CONTRIBUTIONS** 

CEHF drafted infographic, RGM reviewed final image, CH conceived infographic, drafted infographic and reviewed final image.

### **COMPETING INTERESTS**

The authors declare no competing interests.

## Trabeculectomy surgery with MMC





Medication 226 participants

# **OUTCOMES AT 24 MONTHS FOLLOW-UP**



No significant difference in quality of life scores



No significant difference in visual fields



IOP was 2.75 mmHg lower in trabeculectomy vs medication





in the incarcation aim	
	Medical treatment
	44 in 100
	1 in 100

Primary trabeculectomy had similar QOL and safety outcomes and achieved a lower IOP compared with primary medication

Trabeculectomy 39 in 100

### ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to C.H.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 25 June 2021 Revised: 12 July 2021 Accepted: 14 July 2021

Published online: 4 August 2021

<sup>&</sup>lt;sup>1</sup>University College London, London, UK. <sup>™</sup>email: c.henein@ucl.ac.uk